Acadia Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Acadia Pharmaceuticals Inc (ACAD) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Acadia Pharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1,139M vs 20,571M combined for its competitors (5.2% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+8.2% annualized vs trailing 12 months), vs holding steady (-0.6%) for its tracked peer group.
- Growth: Acadia Pharmaceuticals Inc generated 16.4% revenue growth year over year in Q2 2026, vs 27.2% for its competitors combined.
- Profitability: Its 10.2% net margin compares with -13.4% for the peer group.
- Scale: Acadia Pharmaceuticals Inc ranks #70 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.1% of industry market cap.
- Peer revenue share: Acadia Pharmaceuticals Inc accounted for 5.7% of combined revenue among its tracked peer group, down from 6.2% a year earlier.
- Peer differentiation: Revenue per employee of $1.43M compares with $0.77M for the peer group (1.8x).
- Structure: Acadia Pharmaceuticals Inc operates in the following segments: Reportable Segment Aggregation Before Other Operating Segment.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ACAD Sales vs. its Competitors, Q2 2026
Acadia Pharmaceuticals Inc reported revenue growth of 16.40 % year on year in Q2 2026, below its competitors' combined revenue growth of 27.17 %.
With a net margin of 10.23 %, Acadia Pharmaceuticals Inc achieved higher profitability than its competitors (-13.41 %).
Acadia Pharmaceuticals Inc generated 5.68 % of the combined sales of its peer group, down from 6.18 % a year earlier.
API endpoints for this dataset
Acadia Pharmaceuticals Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Acadia Pharmaceuticals Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Acadia Pharmaceuticals Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Acadia Pharmaceuticals Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Acadia Pharmaceuticals Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 16.4% for Acadia Pharmaceuticals Inc. Acadia Pharmaceuticals Inc's share of combined industry revenue moved from 0.06% to 0.06%, a gain of 0.00 percentage points.
Acadia Pharmaceuticals Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Acadia Pharmaceuticals Inc | Yes | Yes | Yes | No |
| Competitors combined (79) | ||||
| High-Confidence Competitors (3) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 75.00 % (6 of 8) | 100.00 % (8 of 8) | 87.50 % (7 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ACAD Stock Performance relative to its Competitors
ACAD Stock Performance relative to High-Confidence Competitors
ACAD Stock Performance relative to Similar-Size Competitors
ACAD Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Inmed Pharmaceuticals Inc | 282.9% | Outperformed |
| 2 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 3 | Climb Bio Inc | 282.9% | Outperformed |
| 4 | Gossamer Bio Inc | 282.9% | Outperformed |
| 5 | Avadel Pharmaceuticals Plc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Acadia Pharmaceuticals Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Acadia Pharmaceuticals Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Acadia Pharmaceuticals Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Acadia Pharmaceuticals Inc |
3,669.63 | 1,138.64 |
 Takeda Pharmaceutical Company Limited |
33,743.89 | 30,079.37 |
 Neurocrine Biosciences Inc |
17,319.08 | 3,701.70 |
 Alterity Therapeutics Limited |
15,544.53 | - |
 Jazz Pharmaceuticals Plc |
15,188.97 | 4,718.13 |
 Madrigal Pharmaceuticals Inc |
12,114.04 | 1,427.94 |
| SUBTOTAL | 213,382.82 | 52,380.88 |
Sign in to see all competitors of Acadia Pharmaceuticals Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Acadia Pharmaceuticals Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Acadia Pharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from Acadia Pharmaceuticals Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Ovid Therapeutics Inc | Company report | 85% |
| Camp4 Therapeutics Corporation | Company report | 85% |
| Harmony Biosciences Holdings inc | Company report | 85% |
| Sage Therapeutics Inc | Company report | 85% |
| Neurocrine Biosciences Inc | Company report | 85% |
| Alkermes Plc | Company report | 85% |
| Amylyx Pharmaceuticals Inc | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Acadia Pharmaceuticals Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Acadia Pharmaceuticals Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Acadia Pharmaceuticals Inc | Reportable Segment Aggregation Before Other Operating Segment 100.00 % |
| Neurocrine Biosciences Inc | Reportable 100.00 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Biomarin Pharmaceutical Inc | Reportable 100.00 % |
| Crinetics Pharmaceuticals Inc | Reportable 100.00 % |
| Alkermes Plc | Single Reporting Segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Acadia Pharmaceuticals Inc .
Acadia Pharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Acadia Pharmaceuticals Inc | 3,670 | 1,426,871 | 476,797 |
| Takeda Pharmaceutical Company Limited | 33,744 | 639,986 | 15,106 |
| Neurocrine Biosciences Inc | 17,319 | 1,850,850 | 351,250 |
| Alterity Therapeutics Limited | 15,545 | - | -715,480 |
| Jazz Pharmaceuticals Plc | 15,189 | 1,632,570 | 71,263 |
| Madrigal Pharmaceuticals Inc | 12,114 | 1,560,590 | -169,905 |
| PEERS TOTAL | 209,713 | 771,383 | -43,612 |
Sign in to see all peers for Acadia Pharmaceuticals Inc .
Acadia Pharmaceuticals Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Jazz Pharmaceuticals Plc | United States 88.39 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.08 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Acadia Pharmaceuticals Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Acadia Pharmaceuticals Inc's industry classification, broader than the peer set above. Market cap in millions of $.Acadia Pharmaceuticals Inc ranks #70 of 495 companies by market capitalization in its industry, holding 0.06 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 70 | Acadia Pharmaceuticals Inc | 3,670 | 0.06 % |
Market cap and industry share for the rest of Acadia Pharmaceuticals Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Acadia Pharmaceuticals Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 65 | Erasca Inc | 4,486 | 437.85 % |
| 66 | Structure Therapeutics Inc | 4,435 | -40.47 % |
| 67 | Biolinerx Ltd | 4,216 | -50.72 % |
| 68 | Xenon Pharmaceuticals Inc | 3,902 | -3.14 % |
| 69 | Organon and Co | 1,234 | 12.3% |
| 70 | Acadia Pharmaceuticals Inc | 3,670 | -7.41 % |
| 71 | Abcellera Biologics Inc | 1,234 | 12.3% |
| 72 | Genmab A | 1,234 | 12.3% |
| 73 | Arcutis Biotherapeutics Inc | 1,234 | 12.3% |
| 74 | Amylyx Pharmaceuticals Inc | 1,234 | 12.3% |
| 75 | Enliven Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Acadia Pharmaceuticals Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Acadia Pharmaceuticals Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 91.13 % | 37.89 % (avg) | +53.2 pp |
| Operating Margin | 7.59 % | industry median | +8.3 pp |
| EBITDA Margin | 11.72 % | -6.23 % (avg) | +17.9 pp |
| Capital Intensity (Capex / Revenue) | 1.29 % | 7.58 % (avg) | -6.3 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Acadia Pharmaceuticals Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 9.9x | 26.6x | -16.7x |
| EV / EBITDA | 26.4x | 15.9x | +10.5x |
| P/B | 3.2x | 4.3x | -1.0x |
| Return on Equity | 32.39 % | industry aggregate | 16.04 % |
| Return on Invested Capital | 3.60 % | -9.83 % (avg) | 13.43 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Acadia Pharmaceuticals Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 275.58 % | -27.72 % | 30.28 % | 9.60 % | 6.83 % | 40.45 % | 31.85 % | 11.87 % |
| Operating Margin | -52.27 % | -72.71 % | -64.87 % | -35.20 % | -43.23 % | -10.10 % | 24.10 % | 9.78 % |
| Return on Invested Capital | -38.50 % | -22.29 % | -21.69 % | -14.31 % | -24.48 % | -8.72 % | 19.16 % | 5.46 % |
| P/E | - | - | - | - | - | - | 11.9x | 10.4x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Acadia Pharmaceuticals Inc's Strategic Group Map
Acadia Pharmaceuticals Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Acadia Pharmaceuticals Inc's trailing-12-month revenue growth of 11.8% and operating margin of 7.6% compares with an average of 12.6% growth and 9.8% margin across its 8 closest peers by combined growth, margin and ROIC -- Acadia Pharmaceuticals Inc sits below that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Acadia Pharmaceuticals Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Acadia Pharmaceuticals Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Acadia Pharmaceuticals Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.29 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Acadia Pharmaceuticals Inc's dedicated Suppliers and Customers pages, not here.
Acadia Pharmaceuticals Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Acadia Pharmaceuticals Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Acadia Pharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 8.3 points above the industry median.
- Return on equity 16.0 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+8.2% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- Trades at a lower P/E than the industry average (9.9x vs 26.6x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of competitors (52.80 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Acadia Pharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Acadia Pharmaceuticals Inc | 0.85 | 3.50 | - |
| Takeda Pharmaceutical Company Limited | 0.15 | 1.01 | 0.58 |
| Neurocrine Biosciences Inc | 0.57 | 2.51 | - |
| Alterity Therapeutics Limited | 9.38 | 12.98 | - |
| Jazz Pharmaceuticals Plc | 0.81 | 1.87 | 1.27 |
| Madrigal Pharmaceuticals Inc | 0.83 | 3.39 | 0.60 |
Sign in to see all peers for Acadia Pharmaceuticals Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Acadia Pharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Acadia Pharmaceuticals Inc | Q2 2026 | +16.4 % | +18.1 % |
| Takeda Pharmaceutical Company Limited | Q1 2025 | +1.8 % | -28.9 % |
| Neurocrine Biosciences Inc | Q3 2026 | +41.2 % | -1.4 % |
| Alterity Therapeutics Limited | Q2 2025 | - | - |
| Jazz Pharmaceuticals Plc | Q3 2026 | +10.4 % | - |
| Madrigal Pharmaceuticals Inc | Q3 2026 | +50.1 % | - |
| PEERS TOTAL | +7.3 % | - |
Sign in to see all peers for Acadia Pharmaceuticals Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Acadia Pharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Acadia Pharmaceuticals Inc | Q2 2026 | +36.6 % | +1,613.5 % |
| Takeda Pharmaceutical Company Limited | Q1 2025 | -8.7 % | +8.5 % |
| Neurocrine Biosciences Inc | Q3 2026 | +104.6 % | -12.1 % |
| Alterity Therapeutics Limited | Q2 2025 | - | - |
| Jazz Pharmaceuticals Plc | Q3 2026 | - | -64.1 % |
| Madrigal Pharmaceuticals Inc | Q3 2026 | - | +1.8 % |
Sign in to see all peers for Acadia Pharmaceuticals Inc .
Acadia Pharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Acadia Pharmaceuticals Inc | 24.38% | 31.05% | 32.39% |
| Takeda Pharmaceutical Company Limited | 0.75% | 0.97% | 1.53% |
| Neurocrine Biosciences Inc | 13.69% | 16.94% | 19.74% |
| Alterity Therapeutics Limited | - | - | - |
| Jazz Pharmaceuticals Plc | 1.77% | 2.12% | 4.62% |
| Madrigal Pharmaceuticals Inc | - | - | - |
Sign in to see all peers for Acadia Pharmaceuticals Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Acadia Pharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Acadia Pharmaceuticals Inc | 9.52 | 3.22 |
| Takeda Pharmaceutical Company Limited | 0.31 | 1.12 |
| Neurocrine Biosciences Inc | 24.34 | 4.68 |
| Alterity Therapeutics Limited | - | - |
| Jazz Pharmaceuticals Plc | 76.47 | 3.22 |
| Madrigal Pharmaceuticals Inc | - | 8.48 |
| PEERS AVERAGE | - | 4.07 |
Sign in to see all peers for Acadia Pharmaceuticals Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.